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EFFECTS OF ISCHEMIA AND REPERFUSION ON MITOCHONDRIAL 
PHOSPHATE UPTAKE IN RAT RENAL PROXIMAL TUBULES. Samer 
Najjar, Norman J. Siegel, Thomas O. Carpenter. Sections of Endocrinology 
and Nephrology, Department of Pediatrics, Yale University School of 
Medicine, New Haven, CT. 
Proximal tubular ATP is depleted in renal ischemia and is partially 
replenished by subsequent reperfusion. Since ATP synthesis is dependent on 
mitochondrial uptake of inorganic phosphate (Pi), we examined the effects of 
ischemia and reperfusion on Pi uptake in mitochondria isolated from rat 
renal proximal tubules. 
Male Sprague-Dawley rats underwent bilateral renal artery occlusion 
for 0 or 45 minutes. Kidneys were collected immediately or following 30 
minutes of reperfusion, and proximal tubules were harvested. Mitochondria 
were isolated and resuspended. 32p labelled Pi was added and serial aliquots 
were pipetted into inhibitor-containing vials. Mitochondrial Pi uptake was 
determined at each time point from the fraction of total added radioactivity 
present in mitochondria. 
Mitochondrial Pi uptake in ischemic rats (0.4 +_ 0.6 nmol Pi/mg 
mitochondrial protein, mean +_ SD) was markedly less than in either 
uninjured controls (13.1 +_ 6.3 nmol Pi/mg mito. protein) (p=0.016) or 
reperfused rats (22.2 + 6.2 nmol Pi/mg mito. protein) (p=0.001). Mitochondrial 

Pi uptake in reperfused rats was not significantly greater than controls 
(p=0.059). 
We conclude that renal proximal tubular mitochondrial Pi transport 1) 
is inhibited during ischemia, when ATP is depleted; 2) recovers to at least 
control levels during post-ischemic reperfusion, when ATP is replenishing. 
These results suggest that mitochondrial Pi uptake in the early reflow period 
is unlikely to be rate limiting for the post-ischemic regeneration of ATP. A 





Ischemia and subsequent reperfusion are pathophysiologic events 
common to many important clinical entities, such as myocardial infarction, 
stroke and acute renal failure. The effects of ischemia and reperfusion on 
tissues, cells, subcellular organelles and biochemical substrates are therefore 
being extensively investigated in many organ systems. 
1) ACUTE RENAL FAILURE 
Our laboratory is particularly interested in examining the 
pathophysiologic processes underlying acute renal failure (ARF) and recovery 
from this injury. ARF is defined as an acute deterioration in the ability of 
kidneys to maintain the homeostasis of body fluids. It is characterized by an 
acute decrease in the glomerular filtration rate and a paralysis of tubular 
function. Unfortunately, the mortality rate for patients with ARF has 
remained unacceptably high, exceeding 60% even in non-elderly patients 
who do not have significant complications (1). 
To date, most of the investigations on experimental ARF have 
uncovered manipulations that could protect the glomeruli and tubules from 
loss of function if applied prior to the ischemic insult. These studies have 
clarified many aspects of the pathophysiology of experimental ARF. Their 
clinical applicability has remained limited however, as physicians are usually 
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faced with the task of treating ARF, not preventing it. What is needed then, 
is the development of interventions that would help overcome and/or 
accelerate the recovery from ARF. This, in turn, requires a thorough 
understanding of the factors that determine the severity of the injury and 
those that modulate the repair process during recovery. 
Our laboratory has been actively engaged in studying the role of one of 
those factors, namely cellular ATP. For a thorough review of the other 
factors, the reader is referred to reference 2 which discusses in detail the 
contributions to ischemic renal cell injury and repair of decreased pH, 
calcium, amino acids, proteases, oxidant injury, heat shock proteins and 
alterations in cell volume, cell polarity and cytoskeleton. 
2) CELLULAR ATP LEVELS DURING ISCHEMIA AND REPERFUSION 
The role of ATP in the energy metabolism of all cells is of paramount 
importance and has been well characterized. Hydrolysis of its high energy 
phosphate bond provides the driving force for many vital cell functions 
including protein synthesis, carbohydrate metabolism, lipogenesis, 
maintenance of cell structure, regulation of cell volume etc. Any insult that 
depletes cellular ATP stores would prevent cells from sustaining these vital 
functions and would therefore contribute to cell injury and ultimately to cell 
death. In particular ischemia, which is known to inhibit mitochondrial 
oxidative phosphorylation (because of anoxia and intrinsic membrane 
alterations), would be expected to lead to cellular ATP depletion. 
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The study of renal cellular ATP during ischemia and reperfusion has 
been greatly aided by the availability of a convenient in vivo animal model 
that mimics ischemic ARF and recovery from this insult: In essence, an 
animal's renal arteries are clamped for a specified amount of time and then 
allowed to reperfuse. Using this model, Warnick and Lazarus (3) showed that 
renal cellular ATP levels rapidly drop to 25% of their control values after 30 
seconds of ischemia, then gradually decrease to 15% and 10% of their control 
values after 5 minutes and 2 hours of ischemia, respectively. Using 31P-NMR 
spectroscopy on in situ kidneys, Siegel et al. (4) and Stromski et al. (5) have 
similarly shown that ATP levels rapidly fall to less than 10% of their control 
values within 10 minutes of ischemia, and remain low for the duration of 
the 45 minute insult. These results are in agreement with the rest of the 
published data (6,7,8,9) that essentially show an 80-90% decrease in ATP levels 
following 10-60 minutes of renal ischemia. 
The recovery of cellular ATP during the ensuing reflow period has also 
been investigated. By unclamping the renal arteries and allowing the kidneys 
to reperfuse for a specified amount of time, Siegel et al. (4) and Stromski et al. 
(5) have shown that ATP regeneration follows a biphasic pattern: An initial 
rapid phase returns ATP levels to 50% of their pre-ischemic values after 15 
minutes of reflow. This is followed by a slower phase during which ATP 
levels return to 60-65% of their pre-ischemic values after 2 hours of reflow. 
Other investigators (6,8) have similarly reported a less than 50% recovery of 
tissue ATP at 1 hour of reflow following a 60 minute ischemic insult. 
The pattern and degree of recovery of cellular ATP is highly dependent 
on the duration of the preceding ischemic interval. Vogt and Farber (6) 
showed that renal ATP levels return to 90% of their control values within 10 
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minutes of reflow if the ischemic interval is less than 20 minutes. On the 
other hand, there is only a 50% recovery of ATP after 1 hour of reflow if the 
ischemic interval is extended beyond 25 minutes. 
In the initial rapid phase of ATP repletion, this ATP is likely generated 
from phosphorylation of cellular AMP and ADP (3,10). Indeed, there is a 
good correlation between ATP levels at the end of this initial rapid phase of 
regeneration and total adenine nucleotide (TAN) levels at the end of the 
ischemic insult (10). The size of the TAN pool (sum of ATP, ADP and AMP) 
decreases with increasing duration of ischemia (3,7) as AMP is converted to 
the purine nucleosides adenosine and inosine and the purine base 
hypoxanthine. These compounds, in turn, increase during ischemia (11). 
Unfortunately, they are not salvageable because they are membrane 
permeable, and they, therefore, diffuse out of the cell and wash out of the 
kidney upon reflow (3). 
During the slower component of nucleotide regeneration, ATP is likely 
derived from net cellular resynthesis (10). This process is dependent on the 
residual nucleotide pool, the availability of precursor compounds and the 
degree of cellular or membrane damage, which reflect the severity and 
duration of the ischemic insult (10). 
3) MANIPULATIONS THAT INCREASE CELLULAR ATP LEVELS DURING 
REFLOW 
The inability of cells to completely replete their ATP stores following a 
prolonged ischemic insult undoubtedly affects their ability to recover from 
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this injury, since the repair processes are all energy-dependent. Therefore, it 
seems likely that manipulations which would increase cellular ATP levels in 
the post-ischemic period should help the recovery process. Indeed, Stromski 
et al. (10) found a strong correlation between cellular ATP levels at 120 
minutes of reflow and post-ischemic renal function. Thus ATP levels at 120 
minutes of reflow can be used as indicators of the severity of the ischemic 
insult. On the other hand, renal function measurements during reflow are 
not good predictors of recovery. Gaudio et al. (12) found that dopamine, 
which enhances renal blood flow, initially improved renal function after 2 
hours of reflow, but failed to sustain this improved function 24 hours later. 
These investigators noted that at 2 hours of reflow, dopamine had not 
significantly changed ATP levels from control values in saline-treated 
animals. 
Since the initial rapid phase of ATP repletion following ischemia is 
dependent on phosphorylation of cellular AMP and ADP, increasing the 
TAN levels at the end of the ischemic insult should help ATP regeneration 
during reperfusion. Stromski et al. (13) succeeded in increasing the TAN 
level at the end of the ischemic interval by administering to rats 2'- 
deoxycoformycin, which blocks the deamination of adenosine to inosine. 
Van Waarde et al. (14) obtained similar results by using the ADP analogue 
adenosine a,fi-methylene diphosphate (AMPCP), which inhibits the 
dephosphorylation of AMP to adenosine. As predicted, the increase in the 
TAN pool size led to a higher recovery of ATP during the initial rapid phase 
of ATP regeneration. Kidney function, as measured by inulin clearance, was 
also significantly improved 24 hours after the insult. Interestingly, the rate of 
ATP restoration over the ensuing 2 hours was also accelerated. This is 
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probably due to an increase in the endogenous precursors for ATP resynthesis 
coupled with a decrease in the amount of cellular and membrane damage. 
The reduction in membrane damage may be due to the decrease in purine 
base formation which decreases the flow through the enzyme xanthine 
oxidase (13), whose activity results in oxygen free radical formation. 
These animal experiments support the contention that ATP generated 
during the initial rapid phase of recovery is dependent on phosphorylation of 
cellular nucleotides. Furthermore, these studies strongly suggest that 
recovery of cellular ATP is rate limiting for the recovery from the ischemic 
injury. The clinical applicability of these observations is unfortunately 
limited, because the compounds that were utilized to block AMP degradation 
needed to be infused before the ischemic injury was administered. 
Manipulations to increase ATP regeneration have also been attempted 
during the slow phase of ATP recovery. Siegel et ai. (4) studied the effects of 
post-ischemic infusion of an ATP-MgCl2 solution to rats. These investigators 
found that whereas the initial rapid phase of ATP regeneration was 
unchanged, renal tissue ATP levels at 2 hours of reflow reached 90% of their 
pre-ischemic values, compared to only 60% in control animals that did not 
receive the ATP-MgCl2 solution (42). ATP-MgCb infusion has also been 
shown to enhance the recovery of renal function (15) and to accelerate the 
restoration of injured tubular epithelium (16). ATP-MgCl2 exerts the bulk of 
its effects by providing precursors for the resynthesis of cellular adenine 
nucleotides (5), which have recently been shown to be taken up by an S-(p- 
nitrobenzyl)-6-thioinosine (NBTI)-sensitive transporter (17). ATP-MgCl2 is 
unlikely to exert its effects via hemodynamic or membrane stabilizing effects 
(5), nor is it likely to serve as a direct source of energy (5). Unfortunately, the 
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clinical applicability of adenine nucleotide infusions for treatment of ARF are 
limited because of their adverse hemodynamic effects. 
Surprisingly, Sutter et al. (18) found that ATP regeneration during the 
slow phase of ATP recovery is also improved by the post-ischemic infusion of 
thyroxin (T4). Recovery of renal function was significantly accelerated and 
was sustained throughout the reflow period. Repair of damaged tubular 
epithelium was also enhanced. In addition to its beneficial effects in ischemia 
induced ARF, T4 has also been shown to be effective in accelerating recovery 
of glomerular and tubular function in toxic ARF (19,20,21,22). T4 is believed 
to act by enhancing mechanisms of recovery rather than by simply limiting 
the severity of the initial insult (18). Its cellular and molecular mechanisms 
of action remain to be determined. They are probably multifactorial, possibly 
including the stabilization of cell membranes (by altering their phospholipid 
composition, their cholesterol and cardiolipin content, their degree of fatty 
acid saturation and their lipid to protein ratio), the stimulation of Na+-K+- 
ATPase and/or of the ADP/ATP translocase (18). To the best of our 
knowledge, there has only been one published report on the clinical use of T4 
for the treatment of ARF. Staub (23) reported a prompt diuresis and recovery 
of function in eight children with ARF treated with T4. This study 
unfortunately lacked a control group. Nevertheless, its promising results and 
the clinical familiarity in using thyroxin, will hopefully generate interest in 




4) EFFECTS OF ISCHEMIA AND REPERFUSION ON THE MOLECULAR 
MECHANISMS OF ATP SYNTHESIS 
It should be evident from all the studies cited that ATP regeneration is 
rate limiting for renal cellular recovery from an ischemic insult. Further 
insights into understanding the cause(s) of the disrupted and suboptimal ATP 
regeneration during reflow may be derived from examining the molecular 
mechanisms that underlie ATP synthesis and how they are affected by 
ischemia and reperfusion. 
ATP is synthesized in the mitochondrial matrix, catalyzed by the 
membrane bound enzyme ATP-synthase. It requires the mitochondrial 
uptake of ADP and inorganic Phosphate (Pi). 
It is well established that ischemia causes mitochondrial dysfunction. 
A specific sequence of mitochondrial morphologic alterations has been 
described: Initially, there is condensation of the mitochondrial matrix, 
dilatation of the inter-cristae spaces and moderate swelling. At this stage 
these changes are still reversible. Longer durations of ischemia result in large 
amplitude swelling, fragmentation of the cristae and formation of flocculent 
densities containing proteins and lipids (2). During the ensuing reperfusion 
period calcium phosphate precipitates appear in the matrix and they are seen 
as granular densities under electron microscopy (24,25). These morphologic 
alterations are accompanied by mitochondrial functional deterioration. ATP 
depletion and acidosis synergistically act to promote this dysfunction (26) via 
mechanisms that include loss of intra-mitochondrial adenine nucleotides, 
deenergization of the inner mitochondrial membrane, decrease in the 
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number and the activity of the nucleotide translocator, activation of 
endogenous phospholipases and accumulation or loss of calcium (27). 
ADP is taken up by mitochondria in exchange for ATP via a carboxy- 
atractyloside (CAT) sensitive transporter. We have only identified one 
published study that has examined the effects of ischemia and reperfusion on 
this exchanger. Henke and Jung (28) showed that following 60 minutes of 
ischemia, the amount of mitochondrial adenine nucleotide translocator 
remaining in the inner mitochondrial membrane, which was determined by 
titrating state 3 respiration with carboxyatractyloside, was only 55% of that 
measured in controls. The activity of this carrier was unfortunately not 
assayed. Interestingly, quantitative recovery of this exchanger occurred over 
several days, suggesting a slow process of resynthesis (28). Ongoing 
experiments in our laboratory are currently examining the immediate effects 
of ischemia and reperfusion on the activity of this transporter (Boydstun et 
al., personal communication). 
Synthesis of ATP also requires the mitochondrial uptake of Pi. Any 
disruption or alteration in this mitochondrial transport process is likely to 
adversely affect mitochondrial synthesis of ATP. The effects of ischemia and 
reperfusion on mitochondrial Pi transport have not been previously studied. 
We hypothesized that mitochondrial Pi uptake may be decreased during the 
ischemic insult and/or during the subsequent reflow period, and that as a 
result, the intramitochondrial availability of Pi as a substrate for ATP 
synthesis, may become the rate limiting factor in the regeneration of ATP, 
which in turn, is the rate limiting step for the renal cellular recovery from an 
ischemic insult. To test these hypotheses, we designed experiments to 
measure proximal tubular mitochondrial Pi uptake in ischemic and 

reperfused rats. Proximal tubules were of particular interest as they are the 
tubular segment most susceptible to ischemic injury (2), and their ATP levels 
during ischemia and reperfusion have been previously well defined and 
shown to be similar to those of whole kidneys (93). 
5) MITOCHONDRIAL Pi TRANSPORTERS 
We herein review the properties of the mitochondrial phosphate 
transport processes and the molecular characteristics of the mitochondrial 
phosphate transporters. 
Phosphate is an essential substrate for cellular growth and replication. 
It is a constituent of nucleic acids, membrane lipids and other biomolecules. 
It is, therefore, a key component of many cellular and subcellular reactions 
including energy metabolism (29). We are particularly interested in renal 
proximal tubular cells, as these are the segment of nephrons that are most 
susceptible to ischemic injury (30). The reabsorption of Pi in proximal 
convoluted tubules has been shown to be affected by alterations in the 
cytosolic demand for Pi (31), and to be regulated by a multitude of hormonal, 
metabolic and dietary factors (for review see reference 32). Limitation of Pi 
availability depletes these cells of many components of oxidative metabolism 
including ATP (33). Not surprisingly, this adversely affects their functional 
capacity and their ability to reabsorb fluid (33). 
There are several cellular phosphate transporters that have been 
described in various tissues (for review see reference 29). We will limit our 
discussion to mitochondrial phosphate transport processes. These were first 

identified by mitochondrial swelling experiments (34). Two major phosphate 
carriers have since been identified on the inner mitochondrial membrane: 
i) The Phosphate Transport Protein (PTP) 
The phosphate transport protein (PTP) is a carrier located on the inner 
mitochondrial membrane. Chappell and Crofts (35) first suggested in 1965 
that this carrier catalyzes the exchange of inorganic phosphate (Pi) for 
hydroxyl anions. This concept was challenged in 1969 by Mitchell and Moyle 
(36) who alternatively proposed that this carrier may catalyze the cotransport 
of Pi and protons. In point of fact, these two processes are experimentally 
indistinguishable (37) and both lead to acidification on the side to which Pi is 
transported. Proving that one of these proposed mechanisms is the 
physiologically correct one will probably require finding appropriate proton 
or hydroxyl anion binding regions on the PTP molecule. Our bias is to 
consider this carrier a Pi/H+ cotransporter, since 1) many carrier molecules 
that bind and co-transport protons have been described, whereas few hydroxyl 
anion carriers are known; and since 2) an abundance of protons is expected to 
be found in the intermembrane space (external surface of the PTP) according 
to Mitchell's chemiosmotic hypothesis (which proposes that protons are 
pumped across the inner mitochondrial membrane as electrons flow through 
the respiratory chain). 
a-Characteristics of the PTP carrier: The stoichiometry of this 
cotransport is 1:1 as determined by the distribution of Pi in respiration- 
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inhibited mitochondria (38). Inorganic phosphate is an anion and a weak 
acid. The ionic species preferentially transported by the PTP under 
physiologic conditions is thought to be the monovalent anion (H2PO4'), even 
though at pH=7.4 Pi is present mostly as the divalent anion (HPO4"). This 
was concluded from kinetic studies which found that the Michaelis constant. 
Km, increases with increasing pH (which increases the fraction of Pi present 
in divalent anion form). Km is defined as the substrate concentration at 
which the reaction rate is half maximal, and in practical terms is an inverse 
measure of the affinity of the enzyme to its substrate. In simpler terms, the 
PTP has a higher affinity for the monovalent anion of Pi (37). 
Freitag and Kadenbach (39) on the other hand challenged this concept, 
and conversely suggested that the divalent anion is the ionic species 
preferentially transported. Their conclusions are based on studies that 
assayed the transport of various substituted analogues of Pi with different 
ionization properties: One of the analogues, a difluorophosphate found only 
in monovalent form was not transported, whereas other analogues that were 
present in both monovalent and divalent forms were transported. These 
findings should be interpreted with caution, however, as they are based on 
mitochondrial swelling experiments, yet control experiments for secondary 
effects such as calcium movement and EDTA-induced permeability changes 
were not done (40). 
The direction of Pi transport is determined by the pH gradient across 
the mitochondrial membrane: Alkalinization of the suspending medium 
leads to Pi efflux from the mitochondria, and conversely acidification leads to 
Pi uptake (41). 

More importantly, the activity of the transporter itself is pH dependent. 
Compounds that dissipate the pH gradient such as ionophores (which allow 
the uptake of protons in exchange for intramitochondrial potassium), block 
Pi transport (42). Similarly uncouplers such as 2,4-dinitrophenol which 
partially dissipate the pH gradient, partially inhibit this transport process (42). 
This pH dependence is of vital importance, as it allows the PTP to transport Pi 
against concentration and electrical potential gradients, by utilizing the 
mitochondrial pH gradient as its driving force (29). It is estimated that as 
much as 25% of the protons extruded by the respiratory chain may be used to 
support this Pi uptake (29). 
The cotransport catalyzed by the PTP is an electro-neutral reaction as 
the monovalent Pi (which is the ionic species preferentially transported) is 
fully coupled to protons (43,44,45). The mitochondrial transmembrane 
electrical gradient does not significantly influence the affinity and the 
maximal transport rate of the PTP. Changing the membrane gradient or 
abolishing it altogether, do not affect the transport of Pi as long as the 
transmembrane pH gradient is kept constant (45). 
Similarly respiration and ATP hydrolysis do not provide a driving 
force, nor do they affect the activity of the PTP. Indeed a greater than 90% 
inhibition of oxidative phosphorylation (achieved by using oligomvcin and 
either rotenone or KCN) does not significantly affect Pi transport (46,47). 
b-Kinetic parameters of the PTP: The kinetic studies of Pi transport 
have greatly been aided by the use of specific inhibitor compounds. Not only 
were these inhibitors used to quench time-dependent reactions, but they also 

allowed the separate measurement of Pi exchange across the 2 major Pi 
transporters (37). More recently, they proved invaluable in the isolation and 
purification of these two carriers (see below). Two important inhibitors will 
be briefly reviewed here: 1) Mersalyl (sodium-X-(3-hydroxymercuri 2- 
methoxypropyl) carbamoyl-phenoxy acetate) is an organomercurial 
compound that reacts reversibly with the exposed SH-groups of cysteine 
residues on proteins (37). As mercurials are highly polar molecules, mersalyl 
can not react with SH-groups residing in apolar environments or within 
mitochondria, nor can it penetrate the inner mitochondrial membrane (37). 
2) N-ethylmaleimide (NEM) is another inhibitor that reacts with SH-groups 
on proteins. This reaction is dependent on temperature, pH, and the 
concentration of maleimide and thiol groups. In contrast to mersalyl, NEM 
reacts irreversibly with the SH-residues, and it does not inhibit Pi transport 
across the dicarboxylate carrier (discussed below). In addition, it is able to 
penetrate the inner mitochondrial membrane. It can therefore act on both 
sides of this membrane and in apolar regions of membrane proteins (37). 
Early measurements of Pi transport were indirect and were inferred 
from studying transport-dependent functions such as ADP stimulation of 
respiration (48,49), or from observing the changes in light scattering due to 
ammonium phosphate induced mitochondrial swelling (50). Direct 
measurements of Pi transport became possible in 1974 when Coty and 
Pedersen (42) introduced an inhibitor-stop technique (described in the 
Methods section) that exploited the characteristic inhibition patterns of the Pi 
carriers. Their results were corroborated by Ligeti et al. (45) who measured Pi 
transport in a similar manner with the exception that the transport process 

was stopped by cessation of substrate supply, not by addition of specific 
inhibitors. 
Pi transport was found to be a typical carrier-mediated process 
exhibiting saturation kinetics. Utilizing indirect methods of Pi transport 
measurement, Fonyo et al. (51) found this transport process to have a low 
affinity for Pi at room temperature (Km =1.95 mM) . Similarly, both Coty 
and Pedersen (42) at 0°C and Ligeti et al. (45) at room temperature obtained a 
Km of 1.60mM with direct methods. As previously mentioned. Km 
decreased with increasing acidity. 
The specific activity (Vmax) of this transport process has also been 
measured. At 0°C, Coty and Pedersen (42) described a Vmax of 205 nmol 
Pi/min/mg mitochondrial protein. At 22°C, Ligeti et al. (45) found this Vmax 
to be 3000 nmol Pi/min/mg mitochondrial protein. This rate is two orders of 
magnitude higher than that for adenine nucleotide transport (2-7 
nmoles/min/mg at 0°C) (52). It is also significantly greater than the overall 
rate of oxidative phosphorylation: The maximal rates of ATP production 
observed in liver mitochondria respiring with pyruvate and succinate are 400 
nmol of ATP/min/mg mitochondrial protein at 10°C (53) and 1000 nmol of 
ATP/min/mg mitochondrial protein at 25°C (54). 
The uptake of Pi in such large quantities suggests that Pi may have 
important mitochondrial functions besides serving as substrate for ATP 
synthesis. These functions are discussed in detail below. 
A more accurate determination of the activity of a carrier is its 
turnover number, which is defined as the number of substrate molecules that 
are transported by the enzyme per unit time, when this enzyme is fully 

saturated with substrate. In essence, the turnover number measures the 
specific activity of a single carrier molecule. It is obtained by dividing the 
specific activity of the carrier by its concentration. The amount of PTP in rat 
liver mitochondria has been estimated to be 50-60 pmol/mg mitochondrial 
protein by Coty and Pedersen (55), Hadavry and Kadenbach (56) and Fonyo 
and Vignais (57) in three separate studies that used three different 
experimental procedures. The calculated turnover number in rat liver 
mitochondria therefore ranges from 3500 min*1 at 0°C (55) to 50,000-60,000 
min*1 at 20-25°C (45). These numbers have recently been questioned by 
Wohlrab (58,59) who calculated a minimum turnover number of 2000-7000 
min*1 at 22°C in reconstituted proteoliposomes containing purified beef heart 
protein. This order of magnitude difference suggests that either the estimated 
amount of PTP in intact mitochondria or the purity and functional integrity 
of the isolated protein need to be re-evaluated (45). 
Nevertheless, these values are higher than the corresponding 
turnover numbers of other membrane transport systems studied in detail, 
such as the mitochondrial adenine nucleotide carrier (500 min*1 and 600 min' 
1 at 18°C in bovine heart and rat liver mitochondria respectively) (60), the 
lactose permease of E. coli (2900 min*1 at 25°C) (61), the brush border 
membrane Na+-glucose transporter (1200 min*1 at 20°C) (62), the chloroplast 
membrane Pi carrier (5000 min*1 at 20°C) (45) and the sarcoplasmic reticulum 
Ca-ATPase (4400-16700 min'1) (63). In contrast to these, the band 3 protein of 
erythrocytes which is responsible for CP/HCO3" exchange has a much higher 
turnover number (50,000 s'1 at 38°C) (64). 

c-Molecular studies of the PTP: The unequivocal determination that 
these kinetic parameters are specific to the PTP itself required that this protein 
be isolated, purified and its activity reconstituted in liposomes. (This very 
tedious process is comprehensively reviewed in reference 34). The isolation 
of this carrier was aided by its irreversible binding to N-ethylmaleimide. 
Unfortunately, this inhibitor reacts covalently with the SH-groups of many 
mitochondrial matrix and inner membrane proteins whose molecular 
weights are similar to that of PTP (~34 Kd), making their separation by gel 
electropheresis very difficult, and necessitating that many procedures be 
designed to increase the specificity of N-ethylmaleimide towards the SH- 
groups of PTP. The purification steps also had to be delicately refined as the 
contaminant proteins turned out to have chemical properties similar to those 
of PTP. Optimal purification required the use of 1) sodium dodecylsulfate 
(SDS) to remove bound lipid or to unfold the protein, and 2) a carefully 
chosen hydroxylapatite ionic exchange chromatographic medium. It was not 
until 1984 that Kolbe et al. (65) succeeded in purifying the PTP from beef heart 
mitochondria to homogeneity. Interestingly, the 2 major contaminant 
proteins sharing similar size and chemical properties with PTP were 
identified as the Pi/dicarboxylate exchanger and the ADP/ATP translocator, 
two mitochondrial carrier proteins functionally related to PTP. 
To date, PTP has been isolated and purified from the mitochondria of 
bovine heart (58,66), porcine heart (67), rat liver (68), rat heart (34), blowfly 
flight muscle (59), and the fungi Sacchnromyces cerivisiae and Candida 
parapsilosis (69). These purified proteins have been incorporated into 
liposomes using a modification of the freeze-thaw-sonication method 

developed by Kasahara and Hinkle (70). This has allowed the reconstitution 
of the activity of the PTP in vitro. 
The biochemical properties and kinetic parameters of the reconstituted 
PTP turned out to be similar to the ones reported above (34). This confirms 
the validity of both Coty and Pedersen's inhibitor-stop technique and Ligeti et 
al.'s rapid filtration technique for measurement of Pi transport across the 
PTP. More importantly, the reconstitution of PTP in a catalytically active 
form should help elucidate the molecular characteristics of Pi transport across 
this carrier. Studies are currently under way (34) to determine whether PTP is 
active as a monomer or a dimer, and whether it is sensitive to autoxidation 
(59,67). Its topology, structural and functional asymmetry in the 
mitochondrial membrane are being investigated (34). Furthermore, the 
molecular structure and the catalytically active sites of the protein are being 
delineated (see below). 
Since PTP is the only transport protein other than bacteriorhodopsin 
(72) that has been rigorously identified, highly purified (65) and its activity 
reconstituted into liposomes (73), understanding the molecular mechanisms 
of Pi transport across the mitochondrial membrane as well as the role of 
individual amino acids in this transport process will greatly contribute to our 
understanding of membrane transport processes in general. In this respect, 
studying the effects of ischemia and reperfusion on mitochondrial Pi 
transport may provide important information about mitochondrial transport 
processes in general. 
The isolation, purification and reconstitution of the activity of the PTP 
has been complemented by the recent sequencing of the amino acid 

composition of the bovine heart PTP (65). This amino acid sequence was 
deduced from the nucleotide sequence of several overlapping clones 
encoding for this carrier protein (74). A full length cDNA clone encoding the 
precursor of the rat liver mitochondria PTP has also been isolated, sequenced, 
characterized and its amino acid composition deduced (75). 
The bovine heart (MW 34,740) and the rat liver mitochondrial Pi 
carriers contain 312 and 313 amino acid residues respectively. Even though 
their kinetic parameters are identical, they differ in 32 amino acids (~10%). 
They show considerable more variability than the P-subunit of the ATP 
synthase enzyme, in which only 5 out of 480 residues differ between the rat 
liver and the beef heart enzymes (29). It therefore appears that more amino 
acid changes are tolerated by the Pi transport proteins than by the fi-subunit of 
ATP synthases. The significance of these changes in these two crucial 
proteins involved in oxidative phosphorylation remains unclear (75). 
In addition to differences among species, there appear to be physical 
(although not functional) differences in PTP among organs of the same 
species. Indeed, the Pi transport proteins from rat heart and rat liver show 
differences in their mobilities, their cyanogen bromide-generated peptide 
maps and in the Western blots of their cyanogen peptides (34). It is not 
known whether these differences are due to alternate mRNA splicing, 
posttranslational processing, multiple genes or a combination of these (34). 
Comparing the amino acid sequence of PTP with those of other known 
proteins such as Pi binding proteins, H+-linked symporters and the human 
glucose transporter does not reveal any significant homologies (75). In 
contrast to many bacterial transporters (E. coli lactose permease, xylose/H+ 
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symporter and melibiose carrier) and to the human erythrocyte glucose 
symporter which all have 12 transmembrane segments, the hydropathy 
profile of the rat liver mitochondrial PTP suggests the presence of only 6 
transmembrane segments per molecule (75), with hydrophobic residues 
comprising 59% of the total protein (which is appropriate for a 
transmembrane protein) (29). If the biologically active form of the PTP turns 
out to be a dimer, which is the case for the ADP/ATP translocator (76), then 
the Pi carrier would functionally have 12 trans-membrane segments (75). 
Understanding the topology and molecular mechanisms of the Pi transporter 
may help clarify the structural and functional significance of this common 
motif that is found in many prokaryotic and eukaryotic carrier molecules. 
With the availability of the amino acid sequence of the PTP, studies to 
determine the site(s) of action of inhibitors were undertaken. Only one of the 
eight cysteine residues found in the bovine heart mitochondrial PTP was 
found to react with N-ethylmaleimide (29). This reactive cysteine is present 
on the external surface of the membrane at position 42 and is flanked by 
positive charges (Lysine 41 and Arginine 43) which are thought to stabilize 
the reactive thiolate anion (78). Ligeti and Fonyo (77) found the reactivity of 
this cysteine 42 thiol group to be affected by alterations in both the external 
pH and the intramitochondrial pH. Since cysteine 42 is present on the 
external surface of the membrane, they speculated that the effects of 
intramitochondrial pH changes are probably transmitted through 
transmembrane steric or conformational alterations. The reactivity of 
cysteine 42 was not influenced by substrate concentrations, suggesting that the 
amino acid residues around the NEM-reactive cysteine do not participate 
directly in substrate binding (77). Rather, Ligeti and Fonyo speculated that 
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this region may play a permissive role in Pi transport: In its free state it would 
allow the PTP molecule to undergo a conformational change that would be 
required for Pi transport; in its blocked state, as when bound to N- 
ethylmaleimide, it would prevent the PTP from undergoing this 
conformational change by sterically interfering with its molecular motion 
(77). 
Recently, Phelps et al. (79) cloned and sequenced the PTP gene from the 
yeast Saccharomyces cerivisiae. The DNA sequence has an overall sequence 
homology of 38% to the bovine heart protein (80), with 33% fewer basic and 
acidic amino acids. The 2073 bases of clone code for 311 amino acids (MW 
32,814) with a hydropathy profile suggestive of 6 transmembrane segments. 
Interestingly, these hydrophobic segments contain most of the conserved 
amino acids. The kinetic parameters of this yeast PTP are similar to those of 
the beef heart protein (79). 
Compared to the PTP from beef heart, the yeast carrier retained its high 
sensitivity towards mersalyl, but lost its sensitivity towards N- 
ethylmaleimide (79). Guerin et al. (69) found that this yeast protein lacks the 
reactive cysteine 42 residue of the beef heart carrier. This supports Ligeti and 
Fonyo's conclusion that cysteine 42 does not participate directly in Pi binding. 
Interestingly, Phelps and Wohlrab (80) succeeded in making this yeast carrier 
sensitive to N-ethylmaleimide by using site-directed mutagenesis that 
replaced threonine at position 43 with a cysteine residue. Since the yeast PTP 
which lacks cysteine 42 retains its sensitivity to mersalyl, this inhibitor must 
react with some other SH group in the protein (69). It is hoped that site- 
directed mutagenesis will help identify this group and better characterize the 
relationship of various SH groups to the function of the PTP. 
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PTP has been grouped into a family of mitochondrial anion transport 
proteins (29) that include the ADP/ATP exchanger and the uncoupling 
protein from brown fat mitochondria. These three proteins have 
significantly homologous primary structures including an internal three-fold 
structural repeat (29). In addition, they all have 6 membrane spanning 
hydrophobic segments, comparable molecular masses (30-34 Kd) and behave 
similarly during purification (80). They are probably encoded in nuclear, not 
mitochondrial DNA, as the N-terminal amino acid sequence of the bovine 
heart PTP fails to match any region of the bovine heart mitochondrial DNA 
(65,78). 
Analysis of the biosynthesis of PTP uncovered a 49-residue leader 
sequence. This sequence is important in protein targetting, and is cleaved 
after the protein is embedded in the mitochondrial membrane (74). This 
presequence is not found in the ADP/ATP exchanger or the uncoupling 
protein from brown fat mitochondria. Analysis of their import into 
mitochondria by deletion mutagenesis revealed that the information needed 
to direct these proteins to mitochondria resides within different segments of 
the proteins themselves (81). These three carriers are believed to have 
evolved from a common ancestral gene by gene duplication of an internal 
repeat corresponding to 100 aa (81). Unlike the other two transporters, the 
PTP is present in prokaryotes, and is therefore believed to be the oldest 
member of the family. The leader sequence of the PTP likely represents an 
early targetting mechanism that was eliminated in the subsequent 
evolutionary development of the other two carriers (81). 
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ii) The Pi/dicarboxylate exchanger 
In contrast to the phosphate transport protein (PTP), the 
Pi/dicarboxylate exchanger which is the other major mitochondrial 
phosphate transporter has not been as extensively investigated. Evidence for 
the presence of an independent Pi carrier separate from the PTP was first 
presented by Chappell and Crofts in 1966 (50). They showed differences in 
sensitivities to Pi transport inhibitors and differences in rates of Pi uptake 
when exchanging Pi for hydroxyl anions versus dicarboxylates. Since that 
time most investigators have supported this concept, although some authors 
have argued for the existence of a single Pi carrier whose transport properties 
are modified upon binding certain inhibitors such as n-butylmalonate or N- 
ethylmaleimide (82). The isolation of PTP and reconstitution of its activity 
into liposomes provided new evidence that strongly supported the existence 
of two separate proteins: The reconstituted PTP retained its N- 
ethylmaleimide sensitivity, kinetic characteristics and catalytic properties, 
while remaining insensitive to n-butylmalonate (66). 
a-Characteristics of the Pi/dicarboxylate exchanger: Unlike the PTP, 
which catalyzes the transport of the monovalent Pi anion, the distribution of 
Pi in respiration inhibited mitochondria suggests that it is the divalent anion 
(HPO4") that is transported across the Pi/dicarboxylate exchanger (38). Pi is 
transported in exchange for the respiratory substrates malate, malonate or 
succinate. The reaction is electroneutral. In addition to catalyzing the 
exchange of Pi for dicarboxylates, the Pi/dicarboxylate carrier can catalyze the 
exchange of Pi to Pi and of dicarboxylates to dicarboxylates. This carrier 

probably has different binding sites for Pi and dicarboxylates (83) as kinetic 
studies have shown an order of magnitude difference between the Km values 
for dicarboxylates and Pi (0.2 and 1.5 mM respectively) (83). In contrast to the 
PTP which has a high substrate specificity, the dicarboxylate carrier can 
additionally bind sulfates, sulfites and thiosulfates (34). 
The driving force for dicarboxylate exchange with Pi is the inner 
mitochondrial membrane Pi gradient (43). This in turn is established at the 
expense of the membrane pH gradient via the PTP. Thus the mitochondrial 
dicarboxylate uptake via the Pi/dicarboxylate carrier is indirectly coupled to 
the inner mitochondrial membrane pH gradient (42). Furthermore, 
dicarboxylates have been shown to be transported in exchange for other 
mitochondrial substrates such as citrate (83) and a-keto glutarate (83). Hence 
the mitochondrial uptake of these substrates is also coupled to the 
transmembrane pH gradient, and it is dependent on the establishment of 
appropriate Pi and dicarboxylate transmembrane gradients via the concerted 
activities of the PTP and the Pi/dicarboxylate exchanger (55). 
b-Kinetic parameters of the Pi/dicarboxylate exchanger: The 
Pi/dicarboxylate exchanger is competitively inhibited by the substrate 
analogues n-butylmalonate and phenvlsuccinate (55) which are substituted 
dicarboxylic acids that have no effect on the PTP. The Pi/dicarboxylate 
exchanger is sensitive to mersalyl only at high doses, but is insensitive to N- 
ethylmaleimide (34). Exploiting these characteristic inhibitor sensitivities, 
Coty and Pedersen (42) measured the kinetic parameters of this carrier using 
their inhibitor-stop technique. They found the Km at 0°C to be 1.76mM, 

which is experimentally indistinguishable from the Km of PTP (1.6 + 0.19 
mM). On the other hand, Vmax of the dicarboxylate carrier was 15 nmol 
Pi/min/mg mitochondrial protein which is significantly lower than that of 
the PTP (205 nmol Pi/min/mg mitochondrial protein). At room 
temperature, Wohlrab found Vmax to be 70 nmol Pi/min/mg mitochondrial 
protein (34). 
c-Molecular studies of the Pi/dicarboxylate exchanger: The 
dicarboxylate carrier has not been purified to homogeneity yet. The best 
purification obtained from a dicarboxylate transport-active preparation 
contains at least six to nine distinct protein bands on SDS-PAGE, with a 
mobility in the vicinity of 30Kd (84). Recently, Saint-Macary and Foucher 
succeeded in incorporating the dicarboxylate exchanger from a detergent 
solubilized rat liver mitochondrial fraction into liposomes (85). This 
exchanger closely resembled the PTP in its behavior during purification, and 
its reconstitution into liposomes similarly required cardiolipin for optimal 
activity (29). To date, no Pi transport activity has been successfully 
reconstituted (29) but a dicarboxylate-dicarboxylate exchange activity has been 
achieved (85). This reconstituted exchange is sensitive to n-butylmalonate 
and mercurials, but not to N-ethylmaleimide (85). In a separate series of 
experiments, Kaplan and Pedersen succeeded in reconstituting malate self¬ 
exchange activity from Pi/dicarboxylate exchangers incorporated into 
liposomes via the freeze-thaw-sonication method (84). Unfortunately, their 
calculated exchange rate at room temperature differed 45-fold from the one 
reported by Saint-Macary and Foucher. This discrepancy may be due to the 
fact that these exchange rates were calculated per unit amount of protein, yet 
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their protein determinations were unreliable because of the presence of high 
concentrations of lipids and detergents (34). 
The membrane concentration and turnover number of this carrier 
have not been determined yet. These would help explain whether the low 
dicarboxylate transport capacity of the rat liver mitochondria is due to a low 
concentration of transport protein(s) that have a high turnover number or to 
a high concentration of protein(s) that have a low turnover number (34). 
iii) Other Mitochondrial Pi transporters 
The PTP and the Pi/dicarboxylate exchanger are the best characterized 
mitochondrial Pi transporters, and they probably account for most of this 
transport. Other mitochondrial Pi carriers have also been reported, but 
neither their kinetic parameters nor the extent of their contribution to Pi 
transport are known. 
Aprille et al. (86) have described an ATP-Mg/Pi exchanger in rat liver 
mitochondria. The transported Pi species is the divalent anion. This 
transporter is insensitive to carboxyatractyloside, but is inhibited by relatively 
high concentrations of mersalyl or N-ethylmaleimide. It has no activity at 
4°C, but it is stimulated by sub-micromolar (0.2-0.8|iM) concentrations of 
calcium. The direction of flow is dependent on the energy status of the cell 
(ie the ATP/ADP ratios in mitochondria and in the cytoplasm). This ATP- 
Mg/Pi exchanger alters the absolute concentrations of ATP, ADP and AMP 
without changing the matrix ATP/ADP ratio. It is therefore believed to 
function in regulating the mitochondrial matrix TAN pool size. This in turn 
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selectively regulates those metabolic activities localized to the mitochondrial 
compartment that have adenine nucleotide dependent steps (eg urea 
synthesis, gluconeogenesis, mitochondrial biogenesis, oxidative 
phosphorylation etc.) (86). 
Toninello et al. (87) have postulated the existence of a liver 
mitochondrial Pi efflux mechanism that is separate from that of Pi influx. 
Through inhibitor sensitivity experiments, they showed that whereas 
mitochondrial Pi uptake was blocked by mersalyl and N-ethylmaleimide in 
the presence or absence of spermine, the inhibition of Pi efflux by both 
mersalyl and N-ethylmaleimide was almost completely reversed by 
spermine. Therefore, they concluded that the pathway for Pi efflux was 
distinct from that for Pi uptake. Unfortunately, their results are difficult to 
interpret because they did not control for the activity of the Pi/dicarboxylate 
exchanger nor did they examine the effects of spermine on this carrier which 
is known to extrude mitochondrial Pi. 
Recently, Kikuchi et al. (88) have characterized an ATP dependent 
mechanism for Pi uptake in rat intestinal mitochondria that is sensitive to 
the mercurial agent p-chloromercuribenzoic acid (p-MB). Their experimental 
design, however, does not preclude PTP from being the active carrier in these 
investigations. Interestingly, they showed that this ATP dependent 
mechanism for Pi uptake was regulated by l,25-(OH)2 vitamin D3. 
Finally, recent experiments (89,90) have disproved a previously 
proposed mitochondrial Pi efflux pathway via an atractyloside sensitive 
(2ATP/2ADP,Pi) exchanger (91). Instead, Kaplan and Pedersen found Pi efflux 
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to occur via the PTP and via a mersalyl-insensitive saturable process that may 
represent a new yet undefined carrier (90). 
6) IMPORTANCE OF MITOCHONDRIAL Pi TRANSPORT 
In this detailed review of mitochondrial Pi transport processes, it 
becomes evident that inorganic phosphate and Pi transport must have many 
important mitochondrial functions besides supplying an elementary 
substrate for oxidative phosphorylation. 
By the sequential action of the PTP, the Pi/dicarboxylate, the 
dicarboxylate/tricarboxylate and the 2-oxyglutarate carriers. Pi couples the 
mitochondrial transport of various citric acid intermediates (such as malate, 
malonate, succinate, citrate and a-ketoglutarate) to the membrane pH and 
controls their distribution between mitochondria and cytoplasm (37). 
Moreover, Pi within the matrix serves as proton-donor for the proton 
pump of the respiratory chain, while Pi transport maintains proton flow (37). 
The modulation and regulation of mitochondrial divalent cation transport is 
dependent upon the co-transport of proton-donating anions such as Pi (42). 
Ligeti et al. (45) speculate that the pH dependent transport of Pi on the 
PTP may function to rapidly equilibrate changes in the transmembrane pH 
gradient, thereby maintaining the proton electrochemical gradient almost 
completely in the form of membrane potential. 
From an evolutionary perspective proper Pi transport across the 
mitochondrial membrane is absolutely essential for life in obligatory aerobic 
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eukaryotic cells. Mutations that damaged the Pi carriers (especially the PTP) 
had to be lethal. These mutations could only occur in eukaryotic cells capable 
of surviving on ATP synthesized in the cytoplasm (eg yeasts and molds) (37). 
McGivan et al. (92) demonstrated that inhibiting Pi transport blocked 
phosphorylation of extra-mitochondrial ADP even when sufficient Pi was 
present inside the mitochondria. Whereas the ADP/ATP exchange was 
inhibited, the ADP/ADP exchange was not affected. They concluded that Pi 
transport may act to neutralize the charge imbalance that results from the 
mitochondrial exchange of ADP3_/ATP4' during oxidative phosphorylation. 
The mitochondrial transport of adenine nucleotides and Pi would therefore 
be indirectly coupled by the requirement for charge compensation. In our 
opinion, these conclusions need to be revisited in light of the fact that Pi 
transport across the 2 major mitochondrial Pi carriers has been shown to be 
electroneutral. 
7) SUMMARY 
In summary, ARF is an important entity with poor clinical outcome. 
Effective therapeutic measures are lacking. A better understanding of the 
pathophysiologic mechanisms underlying the injury and recovery processes 
may provide important insights for designing novel therapeutic options. 
In a rat model that mimics ischemia induced ARF, renal cellular ATP 
is significantly decreased during ischemia. During subsequent reperfusion, 
recovery of ATP follows a biphasic pattern. An initial rapid phase returns 
ATP levels to 50% of pre-ischemic values within 15 minutes. This is 
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followed by a slower phase that returns ATP to 60% of pre-ischemic values 
after 2 hours of reflow. In the rapid phase, ATP is generated from the 
phosphorylation of ADP and AMP, whereas in the slower phase, it is re¬ 
synthesized de novo. 
ATP regeneration is one of the rate limiting steps in the recovery from 
the ischemic injury. Manipulations that increase ATP improve the recovery 
of renal function. 
ATP is synthesized in the mitochondrial matrix and requires the 
uptake of the precursor substrates Pi and ADP. Any disruption in these 
mitochondrial transport processes is likely to adversely affect the synthesis of 
ATP. In particular, the effects of ischemia and reperfusion on mitochondrial 
Pi transport have not been previously studied. We hypothesized that 
mitochondrial Pi uptake may be decreased during the ischemic insult and/or 
during the subsequent reflow period, and that as a result, the 
intramitochondrial availability of Pi may become the rate limiting factor in 
the regeneration of ATP. To test these hypotheses, we designed experiments 




1) PREPARATION OF MITOCHONDRIA FROM RENAL CORTICAL 
SUSPENSIONS ENRICHED IN PROXIMAL TUBULES 
a-Renal Ischemia: Adult male Sprague-Dawley rats weighing 200-250g 
were obtained from Camm (Wayne, NJ) and fed a regular diet. On the day of 
study, animals were anesthetized with Inactin (100 mg Inactin/kg body 
weight) IP. Rats were placed on a heated board and their temperature was 
kept at 36-37.5°C rectally. A tracheotomy was performed to secure the airway 
and aspirate excess lung secretions. The right internal jugular vein was 
isolated and cannulated with a PE-50 polyethylene catheter. Normal saline 
was infused at maintenance rates (1.2ml/hour). A midline abdominal 
incision was performed and the retroperitoneal area was exposed. The 
abdominal aorta, and both the right and the left renal arteries were isolated. 
Rats were divided into control and experimental groups. In the 
control group, animals were sham operated but were not subjected to an 
ischemic insult. In the experimental group, renal ischemia was produced in 
the following manner: Heparin (500 units/kg) was infused through the 
internal jugular vein and allowed to circulate for 10 minutes. A vascular 
bulldog clamp was then placed for 45 minutes on the aorta proximal to the 
origins of the renal arteries. At the end of this ischemic interval, the aorta 
was undamped and the kidneys were allowed to reperfuse for 0 or 30 
minutes. 

b-Procedure for harvesting proximal tubules: Gaudio et al.'s (93) 
modification of the procedure described by Balaban and Mandel (94) was used. 
The aorta was first carefully cannulated with PE-90 tubing just distal to the 
origins of the renal arteries. Then the aorta was tied at 2 sites, one proximal 
to the origins of the renal arteries, and the other distal to the catheter but 
proximal to the origin of the inferior mesenteric artery. To insure that 
solutions infused through the aortic catheter would only perfuse the kidneys, 
the superior mesenteric artery was clamped indirectly by tying several loops 
of proximal small bowel. 
The left renal vein was incised and the kidneys were rapidly flushed 
with 10-15cc of a buffered Ringer's solution that had been equilibrated with 
95%C>2 / 5%CC>2 at 37°C. Ringer's Solution contained 112mM NaCl, 3mM 
KC1, ImM K2HP04, 1.2mM MgS04/ 25mM NaHC03, 1.5mM CaCl2 and the 
metabolic substrates Na-Lactate 4mM, glucose 5.5mM, L-alanine 6mM and 
Na-butyrate ImM. The pH was adjusted to 7.4. Unless otherwise indicated, 
the solution was kept on ice and bubbled with 95%02 / 5%C02- Then 65cc of 
a warmed (45°C) and buffered Ringer's solution that contained 110 mg of 
collagenase and 10 mg of protease was infused at a rate of 3cc/minute. The 
digestion was stopped by flushing the kidneys with lOcc of an ice cold buffered 
Ringer's solution. 
The kidneys were then excised and placed in an ice-cold buffered 
Ringer's solution. All the subsequent harvest procedures were performed on 
ice and all the suspensions were equilibrated with 95%C>2 / 5%C02- The 
capsules were carefully peeled off and the corteces were gently scraped with 
razor blades. The scraped cortical material was suspended in 25cc of buffered 
Ringer's solution, stirred for 15 minutes and then filtered through three 

layers of gauze. This process was performed twice. The filtrate, now an 
enriched suspension of proximal tubules, was washed and allowed to 
sediment by gravity. An aliquot of the sediment was examined under light 
microscopy to confirm the predominance of proximal tubules based on their 
distinct histomorphologic characteristics. 
c-Preparation of mitochondria: All solutions and suspensions were 
kept on ice. The renal cortical suspensions containing proximal tubules from 
2 rats (4 kidneys) were pooled and allowed to sediment by gravity. The 
supernatant Ringer's solution was decanted and the proximal tubules were 
resuspended in an ice cold mitochondrial isolation buffer (220mM mannitol, 
70mM sucrose, 2mM HEPES, ImM EDTA, 0.5mg/ml defatted Bovine Serum 
Albumin (BSA), pH=7.4). The suspension was then homogenized in a 15ml 
glass homogenizer vessel with the use of an overhead stirrer (Wheaton). 
The homogenate was centrifuged using a fixed-angle rotor (Sorvall RC-5B 
Refrigerated Superspeed Centrifuge) at 1,000 g for 10 minutes at 4°C. The 
supernatant was collected and centrifuged at 10,000 g for 10 minutes at 4°C. 
The resultant mitochondrial pellet was resuspended in an appropriate 
amount of isolation buffer to obtain a final protein concentration of 1-2 
mg/ml, and kept on ice. 
2) MITOCHONDRIAL PHOSPHATE TRANSPORT ASSAY 
Mitochondrial Pi transport was assayed according to Carpenter and 
Shiratori's (95) modification of Coty and Pedersen's rapid inhibitor-stop 

34 
technique (96). All solutions were kept on ice throughout the procedure, 
lml of the mitochondrial suspension was mixed with a solution of 
unlabelled inorganic phosphate (Pi) (KH2PO4) to a final Pi concentration of 
5mM. The mixture was diluted with isolation buffer to a final volume of 
2ml and was stirred for 15 minutes to allow the Pi to equilibrate across the 
mitochondrial membrane. Then at time t=0, approximately 40pCi of 
radiolabelled KH2[32P]C>4 (Dupont-New England Nuclear, Boston) were added 
to the suspension. This radioactive Pi had been boiled for three hours in the 
presence of 0.1N HC1 (to de-polymerize any phosphate complexes that may 
have formed) and then neutralized with 0.1N KOH just prior to its use. 
Immediately upon addition of the radioactive Pi, serial 200|il aliquots 
of the mitochondrial suspension were sequentially pipetted at specified time 
intervals into separate vials. Each vial contained 1.8ml of a rapidly stirring 
inhibitor solution containing isolation buffer and the two mitochondrial Pi 
transport inhibitors mersalyl (0.08mM) and n-butylmalonate (0.25mM). An 
electrical switch device that connected the pipette to a chart recorder allowed 
the accurate documentation of the exact sampling time of each pipetted 
aliquot. 
Each pipetted aliquot was stirred for 2 minutes with the inhibitor 
solution and then transferred from the vial to a centrifuge tube. The vial was 
washed with 4ml of isolation buffer to collect any remaining mitochondria, 
and this buffer was added to the corresponding centrifuge tube. Each 
inhibited mitochondrial solution was centrifuged at 10,000 g for 15 minutes at 
4°C. The supernatant was decanted and saved for determination of its 
radioactive counts. The mitochondrial pellet was washed with 4ml of 
isolation buffer and centrifuged again at 10,000 g for 15 minutes at 4°C. The 

supernatant was discarded and the centrifuge tubes were inverted to decant 
any remaining buffer. The mitochondrial pellet was air dried for 15 minutes 
then resuspended in 1ml of 88% formic acid. 
For each mitochondrial preparation an additional control experiment 
was concomitantly performed. The procedure was similar to the one just 
described except that the two inhibitors mersalyl and n-butylmalonate were 
added to the initial mitochondrial suspension 3 minutes prior to the addition 
of the radioactive Pi. Pre-incubating the mitochondria with mitochondrial Pi 
transport inhibitors allowed the determination of the amount of non-specific 
background Pi binding to mitochondria. 
For each pipetted mitochondrial aliquot, the radioactive counts of the 
inhibited mitochondrial suspension and the corresponding supernatant 
solution were determined by adding 0.4ml of solution to 5ml of Ecoscint 
(National Diagnostics) scintillation fluid and placing the mixture in a liquid 
scintillation analyzer (TRI-CARB 1600 CA). 
3) PROTEIN ASSAY 
Protein estimations were determined according to Lowry et al.'s (97) 
protein assay method. All manipulations were performed at room 
temperature on the same day the mitochondria were prepared. Albumin 
standard controls and the original mitochondrial suspension were diluted to 
200pl with distilled water. Each sample was mixed with 2ml of a copper 
alkaline reagent (consisting of 1 volume of a 10% NaC03, 0.1% CUSO4, 0.2% 
K-Tartarate solution, 1 volume of 0.8N NaOH, 1 volume 10% SDS and 5 
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volumes of water). 10 minutes later, 400gl of 0.5N Folin-Ciocalteu phenol 
reagent was added to each mixture. Absorbance readings were performed 30 
minutes later in a spectrophotometer (Pharmacia LKB - Novaspec II) at a 
wavelength of 750nm. A standard curve was constructed from the 
absorbance values of the albumin standards, and the protein concentration of 
the mitochondrial suspension was determined from linear regression 
analysis. 
4) CALCULATIONS 
For each aliquot of the mitochondrial suspension that was added to the 
inhibitor solution at time t, the amount of Pi taken up per unit amount of 
mitochondrial protein was calculated in the following manner: The ratio of 
unlabelled intramitochondrial Pi to unlabelled Pi in the suspension is equal 
to the ratio of the total radioactive counts in the mitochondrial pellet to the 
total radioactive counts in the collected supernatant. This latter ratio is 
proportional to the ratio of the measured radioactive counts in the 
mitochondrial pellet (Mr) to the measured radioactive counts in the collected 
supernatant (Sr). The proportionality factor is 1/6 since the volume in which 
the mitochondrial pellet was resuspended was 1 /6th the volume of the 
collected supernatant. 
The following assumptions regarding mitochondrial Pi transport were 
made: 1) the rate of mitochondrial Pi transport is equal to the rate of 
radiolabelled Pi transport at equilibrium; 2) the net amount of Pi taken up by 
mitochondria and 3) the amount of tracer radiolabelled Pi added are both 
negligible compared to the initial amount of unlabelled Pi (10 pmoles). This 

initial unlabelled Pi (Ip) could thus be used as a measure of the unlabelled Pi 
in the suspension at the end of the transport assay. 
Hence, the formula to calculate the amount of Pi taken up by 
mitochondria per mg mitochondrial protein could be written as 
Mr x Ip 
6 x Sr x Co 
where Mr is the measured radioactive counts in the mitochondrial pellet, Ip 
is the initial amount of unlabelled Pi added, Sr is the measured radioactive 
counts in the collected supernatant and Co is the protein concentration of the 
initial mitochondrial suspension. The units of this formula are nmoles of 
Pi/mg mitochondrial protein. 
This formula is applicable to calculating the amount of unlabelled Pi 
taken up by mitochondria only after the transport of radiolabelled Pi has 
reached a steady state (see the Results section for an explanation). For each 
mitochondrial preparation, the calculated values of Pi uptake were averaged 
to give the mean amount of Pi taken up by mitochondria (Tm). This value 
was corrected for non-specific background Pi binding by substracting the Tm 
of the corresponding control experiment. 
5) STATISTICAL ANALYSIS 
All data are reported as means + SD. One-way analysis of variance tests 
was performed. Post hoc contrast tests by the least-square method were used 
to determine significant factors. These procedures were performed with a 
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The effects of ischemia and reperfusion on mitochondrial Pi transport 
have not been previously investigated. Rat renal proximal tubules were 
harvested from 2 rats (4 kidneys) by a procedure that has been well validated 
(93). Mitochondria from these proximal tubules were prepared according to 
standard techniques. In each preparation, an aliquot was used for the 
standard Pi transport assay, a second aliquot was used for the control assay, 
and a third was used for determining the protein concentration. 
Mitochondrial Pi transport was assayed by a rapid inhibitor-stop 
technique. The assay was performed at 0°C because the temperature- 
dependent mitochondrial Pi transport is sufficiently slow at this temperature 
so that when the mitochondrial samples are pipetted into the inhibitor 
containing vials, the time of mixing and inhibition becomes small compared 
to the sampling time (42). 
For each experiment. Pi transport was determined throughout a time- 
course. Figure 1 shows the results of these assays from a single mitochondrial 
preparation from a control rat. The upper curve represents the standard 
assay, whereas the lower curve represents the accompanying control assay to 
establish background binding, in which the mitochondria were pre-incubated 
with the 2 mitochondrial Pi transport inhibitors mersalyl and n- 
butylmalonate prior to the addition of the tracer Pi. 
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In the standard assay, mitochondrial accumulation of radiolabelled Pi 
can theoretically be extrapolated to an initial value of 0. This accumulation 
then rapidly increases, reaching a steady state within 5-10 seconds. Steady 
state indicates that transport of the tracer Pi has achieved equilibrium (but is 
not indicative of any change in the activity of the mitochondrial phosphate 
transporters which remained at equilibrium throughout the experiment). 
This initial rapid phase of radiolabelled Pi uptake therefore measures the 
rapidity with which tracer Pi achieves equilibrium across the mitochondrial 
membrane. In our experiments, however, this equilibration process was so 
fast that it was beyond the resolution of our technique to measure, even at 
0°C. 
After equilibrium of tracer Pi is achieved, the upper curve in figure 1 
represents the net amount of total Pi taken up by mitochondria. Since extra- 
mitochondrial Pi is kept constant in these experiments, the measured Pi 
uptake represents the difference between initial rates of mitochondrial uptake 
and efflux of Pi. 
Accuracy of the measured Pi uptake was increased by allowing 
mitochondria to equilibrate with unlabelled Pi for 15 minutes prior to 
addition of tracer Pi. This avoids complications (42) such as exchange of label 
with portions of the endogenous phosphate pool, or limitation of Pi uptake 
due to lower rates of coupled processes (eg co-transport of ions needed to 
maintain charge neutrality). 
The lower curve in figure 1 represents the amount of background non¬ 
specific mitochondrial Pi binding. This Pi is either bound on the external 
surface of the inner mitochondrial membrane, or is taken up by 

mitochondria via as yet undefined carriers that are not inhibited by mersalyl 
or n-butylmalonate. 
Mitochondrial Pi uptake was measured in three groups of rats: 
1) Control group: Rats in this group were sham operated but were not 
subjected to any ischemic injury. Figure 1 is a representative assay of 
mitochondrial Pi uptake in a control rat. The upper curve represents the 
standard assay, whereas the lower curve represents the background non¬ 
specific Pi binding. The corrected Tm of mitochondrial Pi uptake in control 
rats was 13.10 + 6.29 nmoles of Pi/mg mitochondrial protein (mean +_ SD) 
(n=4). This figure should be distinguished from the Vmax of the PTP which 
is obtained by measuring the corrected Tm of mitochondrial Pi uptake with 
increasing concentrations of extramitochondrial Pi. 
2) Ischemic group: Rats in this group were subjected to 45 minutes of 
bilateral renal artery occlusion with no subsequent renal reflow. Figure 2 is a 
representative assay of mitochondrial Pi uptake in an ischemic rat. The 
upper curve represents the standard assay, whereas the lower curve 
represents the background non-specific Pi binding. Mitochondrial Pi uptake 
in ischemic rats was comparable to that of inhibited controls, with a corrected 
Tm of 0.38 + 0.59 nmoles of Pi/mg mitochondrial protein (mean + SD) (n=3). 

3) Reperfused group: Rats in this group were subjected to 45 minutes of 
bilateral renal artery occlusion followed by 30 minutes of reflow. Figure 3 is a 
representative assay of mitochondrial Pi uptake in a reperfused rat. The 
upper curve represents the standard assay, whereas the lower curve 
represents the background non-specific Pi binding. The corrected Tm of 
mitochondrial Pi uptake in reperfused rats was 22.2 + 6.17 nmoles of Pi/mg 
mitochondrial protein (mean + SD) (n=3). 
Representative standard assays of Pi uptake from all 3 groups are 
shown in figure 4. Figure 5 compares the corrected mean values of 
mitochondrial Pi uptake among the 3 groups: The corrected Tm of Pi 
transport after 45 minutes of ischemia (0.38 + 0.59 nmol Pi/mg-pro) was 
markedly less than either uninjured controls (13.10 + 6.29 nmol Pi/mg-pro) 
(p=0.016) or reperfused rats (22.2 + 6.17 nmol Pi/mg-pro) (p=0.001). The 




Ischemia and the subsequent reperfusion of ischemic tissue are 
thought to play an important pathogenetic role in the tissue injury which 
occurs in many clinical settings, such as acute renal failure (ARF). Working 
in a rat model that mimics ARF, Siegel et al. (4) and Stromski et al. (5) have 
shown that during 45 minutes of ischemia, renal ATP levels rapidly fall to 
less than 10% of their control values and remain low for the duration of the 
insult, and that during reperfusion cellular ATP is regenerated in a biphasic 
manner: An initial rapid phase returns ATP to 50% of pre-ischemic values 
within 15 minutes of reflow; ATP in this phase is derived from 
phosphorylation of endogenous AMP and ADP. An ensuing slower phase of 
ATP regeneration further increases cellular ATP to 60-65% of pre-ischemic 
values after 2 hours of reflow; ATP in this phase is derived from net cellular 
resynthesis. Furthermore, these investigators showed that recovery of 
cellular ATP was one of the rate limiting steps in the recovery from the 
ischemic injury (10), and that manipulations that increased ATP regeneration 
improved the recovery of renal function (4,13,14,18). 
ATP is synthesized in the mitochondrial matrix and requires the 
mitochondrial uptake of the precursor substrates ADP and inorganic 
phosphate (Pi). Any alteration in these mitochondrial transport processes is 
likely to affect mitochondrial synthesis of ATP. Understanding the 
disruption of these transport processes would not only help elucidate the 
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molecular mechanisms underlying the suboptimal regeneration of ATP 
following an ischemic insult, but might also aid in finding novel and 
effective therapeutic modalities that would protect the cell from injury 
and/or enhance its repair mechanisms during reperfusion. 
We therefore elected to investigate the effects of ischemia and 
reperfusion on mitochondrial Pi uptake in order to determine whether this 
transport process is the rate limiting step in the regeneration of ATP 
following an ischemic injury. 
Isolation of mitochondria 
Mitochondria were isolated from rat renal proximal tubules. This has 
not been previously reported. Proximal tubules are of particular interest as 
they are the tubular segment most susceptible to ischemic injury (2). Their 
ATP levels during ischemia and reperfusion have been previously well 
defined and shown to be similar to those of whole kidneys (93). Pi uptake 
was measured in mitochondria prepared from control, ischemic and 
reperfused rats. 
Mitochondrial Pi uptake in control rats 
Proximal tubuler mitochondrial Pi uptake in control rats was 13.10 + 
6.29 nmoles of Pi/mg mitochondrial protein (mean + SD) at 0°C. This figure 
is consistent with the two other reported measurements of mitochondrial Pi 
uptake at 0°C: Coty and Pedersen (42) found it to be 16.6 nmoles of Pi/mg 

mitochondrial protein in rat liver mitochondria (no error given), and 
Carpenter and Shiratori (95) found it to be 12.48 + 5.37 nmoles of Pi/mg 
mitochondrial protein in murine renal cortical mitochondria. 
Since the Vmax of the PTP (42,45) is significantly greater than both the 
Vmax of the ADP/ATP translocator (52) and the maximal rate of ATP 
production (53,54), it is therefore unlikely for Pi transport to be the rate 
limiting step in the synthesis of ATP under physiologic conditions (45,55). 
Mitochondrial Pi uptake in ischemic rats 
This is the first reported study of mitochondrial Pi transport under 
ischemic conditions. In rats subjected to 45 minutes of bilateral renal 
ischemia with no reflow, renal proximal tubuler mitochondrial Pi uptake 
was completely inhibited. This result is consistent with earlier observations 
that i) the PTP is responsible for most of the Pi taken up by mitochondria; ii) 
the PTP is pH-dependent; and iii) the mitochondrial pH gradient is dissipated 
during ischemia because the respiratory chain is inhibited by anoxia. 
Although the dissipation of the mitochondrial pH gradient deprives 
the PTP of its driving force (proton gradient) in vivo, this does not explain 
the inhibition of mitochondrial Pi uptake as measured in our in vitro system. 
Indeed, all our experiments were performed at pH=7.4, whereas cells and 
mitochondria during ischemia are known to become acidotic (2). A pH 
gradient was thus artificially created in vitro, but it did not reverse the 
inhibition of the PTP. This suggests that ischemia may have altered the PTP 
into an inactive state. In light of Ligeti and Fonyo's (77) finding that the 
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reactivity of the cysteine 42 thiol group is affected by intramitochondrial pH 
changes that are probably transmitted through transmembrane steric or 
conformational alterations, it would be interesting to speculate that similarly, 
inactivation of the PTP may be due to an intramitochondrial acidosis-induced 
transmembrane conformational steric change in one or more regions of the 
molecule that would prevent the PTP from undergoing a conformational 
change required for Pi transport. 
Paradies and Ruggiero (71) found the activity of the PTP in 28 month- 
old rats to be significantly less than that in 5 month-old animals. These 
investigators compared mitochondria from young and aged rats and found 
their pH gradients to be the same, their internal exchangeable Pi pools to be 
the same, the amount of PTP in their membranes to be the same, the affinity 
(Km) for Pi of these PTP to be the same and their respiratory activities to be 
the same. The only difference they detected was in the lipid composition of 
their inner membranes. The older rats had a decreased content of the 
phospholipid cardiolipin (diphosphatidylglycerol) and the fluidity of the 
membrane was consequently decreased. Furthermore, Paradies and Ruggiero 
demonstrated that restoring the levels of cardiolipin in the mitochondrial 
membrane with the use of acetyl-L-carnitine increased the activity of the PTP 
to levels found in the 5 months old rats (98). Similarly, reconstitution 
experiments have demonstrated that the activity of the reconstituted PTP is 
strongly influenced by the lipid and protein composition of its 
microenvironment (34). Ischemia is known to induce a loss of membrane 
phospholipids and accumulation of membrane disruptive breakdown 
products such as long chain acyl-CoA esters (2). Such alterations in the 
microenvironment of the PTP probably contribute to disrupting its transport 

activity during ischemia, but they are unlikely to account for the complete 
inhibition of its activity. 
Henke and Junge (28) showed that following 60 minutes of ischemia, 
the amount of mitochondrial adenine nucleotide translocator remaining in 
the inner mitochondrial membrane was only 55% of that measured in 
controls, and that the quantitative recovery of this exchanger occurred over 
several days, suggesting a slow process of resynthesis. We did not measure 
the amount of PTP present in the mitochondria following the ischemic 
insult. It is possible that this amount may be decreased during ischemia, but 
this would not explain the complete inhibition of the activity of the PTP. It is 
unlikely for the mitochondrial membrane to become completely depleted of 
PTP, since mitochondrial Pi uptake was measurable within a few minutes of 
reflow (data not shown) and was 70% above control values within 30 
minutes of reflow, which would require energy depleted cells to rapidly 
resynthesize and incorporate new PTP molecules. 
Instead of postulating an inhibition of mitochondrial transport 
processes, the lack of Pi uptake during ischemia could alternatively be 
attributed to Pi leakage through damaged mitochondrial membranes. We 
believe this is an unlikely explanation because: 1) it would require that all 
mitochondria incur membrane damages, and that some mitochondria 
succeed in repairing this damage within a few minutes (when mitochondrial 
Pi uptake is again measurable), a highly improbable biological event; 2) given 
the depletion of intramitochondrial Pi stores, the mitochondrial Pi gradient is 
more likely to favor Pi uptake - not efflux - through the damaged membrane. 
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In summary, mitochondrial Pi uptake in rat renal proximal tubules is 
completely inhibited following 45 minutes of ischemia. The inhibition is 
mainly due to the dissipation of the mitochondrial pH gradient and to 
inactivation of the PTP possibly through conformational changes in the 
carrier molecule itself. Other factors such as alterations in the membrane 
composition, decrease in the mitochondrial content of PTP or damage to the 
mitochondrial membrane do not significantly contribute to the inhibition 
process. The inhibition of mitochondrial Pi uptake, however, is unlikely to 
be solely responsible for the lack of ATP synthesis during ischemia. Indeed, 
the pH gradient dependent ATP-synthase enzyme is also likely to be inhibited 
as anoxia blocks the respiratory chain and dissipates the proton gradient. On 
the other hand, the activity of the ADP/ATP translocator during ischemia is 
not known. Investigations to assess the effects of ischemia on this carrier are 
currently under way in our laboratory (Boydstun et al. personal 
communication). 
Mitochondrial Pi uptake during post-ischemic reperfusion 
In rats subjected to 45 minutes of bilateral renal ischemia followed by 
30 minutes of renal reflow, mitochondrial Pi uptake not only recovered from 
its nadir during ischemia, but was also slightly (although not significantly) 
greater than control values. 30 minutes of reflow corresponds to the initial 
rapid phase of post-ischemic ATP recovery. During this phase, ATP is 
regenerated from the phosphorylation of the intracellular pool of AMP and 
ADP, which requires an abundant supply of intramitochondrial Pi. 
Nevertheless, since the Vmax of the PTP in control rats is significantly greater 

than the maximal capacity of mitochondria to synthesize ATP, and since 
mitochondrial Pi uptake during reflow is at least as great as control values at 
a time when ATP regeneration is depressed, it is therefore unlikely for 
mitochondrial Pi transport during early reperfusion to be the rate limiting 
step in the resynthesis of ATP. This lends support to previous studies that 
had pointed to the total adenine nucleotide (TAN) pool at the end of the 
ischemic insult as the possible rate limiting factor in the regeneration of ATP: 
TAN levels at the end of the ischemic injury correlate well with the ATP 
levels at the end of this initial rapid phase of regeneration (10), and 
manipulations that increase the TAN pool (either by blocking the 
deamination of adenosine to inosine (13) or by inhibiting the 
dephosphorylation of AMP to adenosine (14)) increase cellular ATP levels. 
The increased mitochondrial uptake of Pi during post-ischemic reflow 
is most likely due to either an increase in the activity of the PTP which, as 
detailed above, is determined by the transmembrane pH gradient, or to a 
recruitment of a greater number of PTP molecules into their active states, 
possibly through intramitochondrial pH induced conformational change(s) 
in the carrier molecules themselves. Interestingly, these conformational 
changes which were first suggested by Ligeti and Fonyo (77), function to 
inhibit the PTP during ischemia when mitochondria are unable to synthesize 
ATP, and to increase the activity of the PTP during reflow to at least control 
levels, when cells need to enhance their depleted ATP stores. We would like 
to propose a model whereby the mitochondria utilize intramitochondrial pH 
as an internal signal to allow the upregulation or downregulation of the 
activity of the PTP depending on the mitochondrial need and/or ability to 
utilize Pi. Further molecular studies of the topology of the PTP and the steric 

properties of its catalytically active sites are required before the existence of 
these pH dependent conformational changes could be confirmed and the 
validity of our model tested. Nevertheless, intramitochondrial pH itself may 
have important regulatory functions. The transmembrane pH gradient on 
the other hand, is known to be utilized by mitochondria for catalyzing the 
activity of the ATP synthase, for taking up Pi against a concentration and an 
electrical gradient, and for regulating the supply of citric acid intermediates 
(37). 
In addition to the transmembrane pH gradient and to the 
intramitochondrial pH, the increase in the activity of the PTP and/or the 
increase in the number of molecules during reflow could also be due to 
alterations in the microenvironment. Paradies and Ruggiero (99) showed 
that liver mitochondrial Pi transport was greater in rats that had been treated 
for 5 days with thyroxin than in control rats. Conversely, they demonstrated 
(100) that this Pi transport was 40% less in rats that had been made 
hypothyroid by treatment with 6-n-propyl-2-thiouracil (PTU) for 3-4 weeks, 
than in control rats. In both studies, the only difference found between 
control and experimental rats was in their mitochondrial lipid composition. 
In rats treated with thyroxin, the phospholipid content of the membrane, 
especially cardiolipin, was increased, whereas the cholesterol content was 
decreased. These alterations decreased the viscosity of the inner 
mitochondrial membrane and increased the mobility of its proteins. The 
opposite membrane changes were found in the rats treated with PTU. These 
membrane alterations followed 1-3 weeks of treatment with T4 or PTU. In 
contrast, Staub et al. (18) found that the post-ischemic infusion of thyroxin 
had an immediate beneficial effect on ATP levels during the slow phase of 

ATP recovery. Experiments are currently under way in our laboratory to 
determine the immediate effects of thyroxin infusion on mitochondrial Pi 
uptake. Since Pi transport is unlikely to be rate limiting for the synthesis of 
ATP, we are also investigating the effects of thyroxin administration on the 
activity of the ADP/ATP translocase (Boydstun et al. personal 
communication). 
Future studies will determine mitochondrial Pi uptake at 2 hours of 
reflow. This will provide an indication of Pi transport during the slow phase 
of post-ischemic ATP regeneration. Since the Vmax of the PTP in control rats 
is significantly greater than both the Vmax of the ADP/ATP translocator and 
the maximal rate of ATP production, and since Pi uptake at 30 minutes of 
reflow is at least as great as control values at a time when ATP synthesis is 
depressed, we predict that the mitochondrial Pi uptake at 2 hours of reflow 
will not be rate-limiting for the synthesis of ATP. If this uptake at 2 hours of 
reflow remains above control values, it would be interesting to speculate 
about the reasons for the excess mitochondrial Pi uptake: 1) mitochondria 
could be in need for more citric acid cycle intermediates, the uptake of some 
of which is coupled to the establishment of the mitochondrial Pi gradient; 2) 
the re-activation of the respiratory chain could require excess protons, and Pi 
within the matrix serves as a proton-donor to the proton pump; 3) the excess 
mitochondrial Pi uptake may be simply a response to the transmembrane pH 
gradient or to the existing intramitochondrial pH, without necessarily having 
a physiological or a teleological role. 
In any case, the excess Pi taken up may have a deleterious effect on 
mitochondria. Indeed, it has been shown that after 6 hours of reflow, there is 
a progressive deterioration in mitochondrial respiration (101). This coincides 

with a gradual accumulation of calcium in mitochondria, which is thought to 
be due to a passive movement of calcium across the mitochondrial 
membrane secondary to an increase in cytosolic calcium. However, the 
accumulation of calcium does not by itself have any deleterious effects on the 
mitochondrial membrane (101,102). Damage to this membrane occurs only 
when Pi is also accumulated in mitochondria (103), at which point calcium 
phosphate precipitates appear in the matrix and are seen as granular densities 
under electron microscopy (24,25). Thus the excess Pi taken up during 
reperfusion may contribute to the deleterious processes that affect 
mitochondria during the later stages of reflow. In theory, partial inhibition of 
this transport process during reperfusion may prevent mitochondrial 
dysfunction and the ensuing cell injury. 
Summary 
In summary, we isolated mitochondria from renal proximal tubules of 
control, ischemic and reperfused rats, and determined Pi uptake. 
Mitochondrial Pi uptake was inhibited during ischemia, but recovered to at 
least control values during reperfusion. Thus, it is unlikely that 
mitochondrial Pi uptake is the rate-limiting step in the post-ischemic 
resynthesis of ATP. It may however have a detrimental effect on 
mitochondria during reperfusion. 
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LEGEND 
Figure 1: Mitochondrial Pi uptake in a control rat. Control rats were sham 
operated but were not subjected to any ischemic insult. The upper 
curve represents the standard assay; the lower curve represents the 
accompanying control assay, in which the mitochondria were pre¬ 
incubated with the 2 mitochondrial Pi transport inhibitors mersalyl 
and n-butylmalonate prior to the addition of the tracer Pi, to determine 
background non-specific binding of Pi to mitochondria. 
Figure 2: Mitochondrial Pi uptake in ischemic rats. Ischemic rats were 
subjected to 45 minutes of bilateral renal artery occlusion with no 
subsequent reflow. The upper curve represents the standard assay; the 
lower curve represents the accompanying control assay for background 
non-specific binding of Pi to mitochondria. 
Figure 3: Mitochondrial Pi uptake in reperfused rats. Reperfused rats were 
subjected to 45 minutes of bilateral renal artery occlusion followed by 
30 minutes of reflow. The upper curve represents the standard assay; 
the lower curve represents the accompanying control assay for 
background non-specific binding of Pi to mitochondria. 
Figure 4: Mitochondrial Pi uptake in control, ischemic and reperfused rats. A 
representative standard assay from each group is shown. 

Figure 5: Comparison of the corrected mean values of mitochondrial Pi 
uptake (corrected Tm's) between control, ischemic and reperfused rats. 
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